Villalba CJ, Martínez HR

Language: Spanish
References: 24
Page: 150-157
PDF size: 65.26 Kb.

ABSTRACT

Introduction: The aim of the present work was to determine the frequency of malignant mesothelioma (MM), the clinical status of MM according to the Butchart staging system, to determine the most frequent symptomatology of MM, the radiological images that predominate, revise the effectivity of diagnostic procedures and the treatment options at the National Institute for Respiratory Diseases (INER). Material and methods: Clinical history of all the cases of MM registered between January 1st, 1998 and December 31st, 2002 in the clinical archive of the Pathology Unit of the INER were analyzed. Results: Sixty-five cases with MM were diagnosed; 49 (75.38%) were men and 16 (24.62%) were women. The most frequent age group for MM in men was 51 to 60 with 40%, the second most frequent group was from 61 to 70 years of age with 20% between men and women. Discussion: During the five years analyzed, cases of MM were more frequent in 2000 with 28 cases (4.12%) followed by the year 1999 with 14 cases (2.04%) of the total of tumors registered at the INER. The 65 cases with diagnosis of MM constituted 2.2% of the total of tumors registered at the INER, which compared to other national and international studies shows a relative increase in the amount of MM at INER. Regarding Buthart´s staging system of pleural mesotheliomas, the most frequently found was stage II with 42 cases (64.62%).

REFERENCES

1. Ruffie P, Feld R, Minkin S. Diffuse malignant mesothelioma of the pleura in Ontario and Quebec. A retropspective study of 332 patients. J Clin Oncology 1989; 7:1157-1168.

2. Tammilehto L, Masilta P, Kostiainen S. Diagnosis and prognostic factors in malignant pleural mesothelioma: A retrospective analysis of sixty-five patients. Respiration 1992;59:129-135.

3. Sugarbaker DJ, Strauss Gm, Linch TJ. Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma. J Clin Oncology 1993;11:1172-1178.

4. Sugarbaker D, Harpole D, Healey E. Multimodality treatment of malignant pleural mesothelioma (Mpm); results in 94 consecutive patients. Proc Am Soc Clin Oncol 1995;14;A-L083,356.

5. Chailleux E, Dabouis G, Pioche D. Prognostic factors in diffuse malignant pleural mesothelioma: A study of 167 patients. Chest 1988;93:159-162.

6. Adams VI, Unni KK, Jr. Diffuse malignant mesothelioma of pleura: Diagnosis and survival in 92 cases. Cancer 1986;58:1540-1551.

7. Boutin C, Reyf. Thoracocopy in pleural malignant mesothelioma: A prospective study of 188 consecutive patients-part 1: Diagnosis. Cancer 1993;72:389-393.

8. Rusch VW, Piantadosi SP, Holmes EC. The role of extrapleural pneumonectomy in malignant pleural mesothelioma. J Thorac Cardiovasc Surg 1991;L02:1-9.

9. Rusch V, Saltz L, Venkatraman E. A phase Ii trial of pleurectomy/decortication followed by intrapleural and systemic chemoterapy for malignant pleural mesothelioma. J Clin Oncol 1994;12:1156-1163.

10. Ball Dl, Creuickshank DG. The treatment of malignant mesotheliomas of the pleural: Review of a 5-year experience, with special reference to radiotherapy. Am J Clin Oncol 1990;13:4-9.

11. Weissmann LB, Antman KH. Incidence, presentation and promising new treatments for malignant mesothelioma. Oncology (Hunting) 1989;3:67-72.

12. Martini N, Mccormack PM, Bains MS. Pleural mesothelioma. Ann Thorac Surg 1987;43:113-120.

13. Vogelzang NJ. Malignant mesothelioma: Diagnostic and management strategies for 1992. Semin Oncol 1992;19 (4,Suppl)11: 64-71.

14. Boutin C, Viallat Jr, Rey R. Thoracoscopy in diagnosis, prognosis and treatment of mesothelioma. In: Antman K, Aisner J, editors. Asbestos-Related malignancy. Orlando:Grune & Stratton, 1987:301-321.

15. Butchart EG, Ashcroft T, Barnsley WC. The role of surgery in diffuse malignant mesothelioma of the pleura. Semin Oncol 1981;8:32l-328.

16. Ong ST, Vogelzang NJ. Chemotherapy in malignant pleural mesothelioma: A review. J Clin Oncol 1996;14:L007-1017.

17. Rusch VW, Figlin R, Godwin D. Intrapleural cisplatin and cytarabine in the management of malignant pleural effusions: A lung cancer study group trial. J Clin Oncol 1991;9: 313-319.

18. Colt HG. Mesothelioma epidemiology, presentation and diagnosis. Semin Respir Crit Care Med 1997; 18:353-361.

19. Rush VW. Treatment of malignant pleural mesothelioma. Semin Respir Crit Care Med 1997;18:363-373.

20. Rusch VW. A proposed new international tnm staging system for malignant pleural mesothelioma. Chest 1995;108:1122-1128.

21. García LMP, Barrera-Rodríguez R. Mesotelioma maligno: Descripción clínica y radiológica de 45 casos con y sin exposición a asbesto. Salud Pública Mex 2000; 42:511-519.

22. Peto J, Hodgsonjt MFE, Joves JR. Continuing increase in-mesothelioma mortality in- britain. Lancet 1995;345:535-539.

23. Berrey M. Mesothelioma incidence-and community asbestos exposure. Environres 1997;9:1206-1210.

24. Yates DHC, Stidolph PN, Browne K. Malignant mesothelioma in Southeast England. Clinicopathological experience of 272 cases. Thorax 1997;52:507-512.